Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 17/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 17/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22179330 | 1.00 | GNAI3 (0.49) | GNAI3GNAO1GNAI1NAAAGLA | |
| SCHEMBL22179385 | 1.00 | GNAI3 (0.49) | GNAI3GNAO1GNAI1NAAAGLA | |
| SCHEMBL22179103 | 0.93 | TLR2 (0.57) | TLR2TLR1 | |
| SCHEMBL22179032 | 0.93 | TLR2 (0.57) | TLR2TLR1 | |
| SCHEMBL22179120 | 0.91 | KMT2A (0.53) | NAAAGLAHSD17B10 | |
| SCHEMBL22179111 | 0.89 | TLR2 (0.60) | TLR2TLR1 | |
| SCHEMBL25021716 | 0.87 | TLR2 (0.50) | TLR2TLR1 | |
| SCHEMBL7234470 | 0.82 | NAAA (0.55) | NAAATLR2TLR1 | |
| SCHEMBL22622323 | 0.79 | GLA (0.70) | GLAHSD17B10 | |
| SCHEMBL22160653 | 0.78 | NAAA (0.61) | GNAI3GNAO1GNAI1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | GNAI3 2266/4885GNAO1 1783/4885GNAI1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.